Welcome to the new version of CaltechAUTHORS. Login is currently restricted to library staff. If you notice any issues, please email coda@library.caltech.edu
Published December 2017 | Published
Journal Article Open

Pseudotyped Lentiviral Vectors: One Vector, Many Guises

Abstract

Viruses have evolved specialized molecular mechanisms to transfer their genome efficiently into host cells. Viruses can be repurposed into viral vectors to achieve controlled gene transfer to desired cells. One of the most popular class of vectors, lentiviral vectors, transduce mammalian cells efficiently. Lentiviral vectors are pseudotyped with various heterologous viral envelopes to alter their tropism. While the most common example is the envelope glycoprotein from vesicular stomatitis virus (VSVG), many other viral proteins have also been used. Pseudotyping lentiviral vectors with a diverse set of naturally occurring or engineered viral envelopes has allowed targeted infection of specific cell types. Many exciting studies are further uncovering new specificities and shortcomings of pseudotyped lentiviral vectors. These studies will expand the toolbox to make lentiviral vectors that cater to the specific requirements of transduction. In this review, we provide a comprehensive overview of various viral envelope pseudotypes used with LVs, their specificity, advantages, and drawbacks.

Additional Information

© 2017 Mary Ann Liebert, Inc. publishers. Accepted: 05 16 2017; Received: 05 16 2017. Online Ahead of Editing: September 4, 2017. We thank Dr. Donald B. Kohn and Dr. Roger P. Hollis for comments and suggestions on the manuscript. A.V.J. and S.S. are supported by Caltech Innovation Initiative (CI2) award and the California Institute of Regenerative Medicine award DISC2-09123. S.S. is a full time employee of PACT Pharma, Inc. A.V.J. has no financial disclosures.

Attached Files

Published - hgtb.2017.084.pdf

Files

hgtb.2017.084.pdf
Files (135.8 kB)
Name Size Download all
md5:d3bf270d2eea812332fca54c4cb4aa98
135.8 kB Preview Download

Additional details

Created:
August 19, 2023
Modified:
October 17, 2023